<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04325932</url>
  </required_header>
  <id_info>
    <org_study_id>UK-001</org_study_id>
    <nct_id>NCT04325932</nct_id>
  </id_info>
  <brief_title>Study of Urinary Kallikrein to Enhance Collateral Circulation in Symptomatic Intracranial Atherosclerosis</brief_title>
  <official_title>Study of Urinary Kallikrein to Enhance Collateral Circulation in Symptomatic Intracranial Atherosclerosis: a Study Based on Whole-brain CTP</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Urinary Kallikrein has an additional effect
      on enhancing collateral circulation in symptomatic intracranial atherosclerotic patients
      under clopidogrel and aspirin dual antiplatelet therapy.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date type="Actual">January 2016</start_date>
  <completion_date type="Actual">July 2019</completion_date>
  <primary_completion_date type="Actual">May 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>the percentage of patients with modified Rankin Score (mRS) equivalent to or less than 2</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>rLMC scale of Collateral circulation</measure>
    <time_frame>2 weeks, 1 month</time_frame>
    <description>We use regional leptomeningeal score(rLMC) score to measure collateral circulation.rLMC score is based on scoring pial and lenticulostriate arteries in 6 ASPECTS regions(M1-6) plus anterior cerebral artery region and basal ganglia. Pial arteries in the Sylvian sulcus are scored 0,2, or 4.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NIHSS score</measure>
    <time_frame>2 weeks, 1month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hemorrhageic complications</measure>
    <time_frame>2 weeks, 1 month, 3 months, 6 months</time_frame>
    <description>Hemorrhageic complications including intracranial, digestive tract</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>New stroke or transient ischemic attack(TIA)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Intracranial Arteriosclerosis</condition>
  <condition>Collateral Circulation</condition>
  <condition>Anterior Cerebral Circulation Infarction</condition>
  <arm_group>
    <arm_group_label>Urinary Kallikrein group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Urinary Kallikrein for injection, 0.15PNA IU,qd, for 2 weeks, administered within 96 hours after TIA or acute ischemic stroke, with basic therapies like dual antiplatelet therapy, blood pressure-lowering therapy and lipid-lowering therapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>with basic therapies like dual antiplatelet therapy, blood pressure-lowering therapy and lipid-lowering therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Urinary Kallikrein</intervention_name>
    <arm_group_label>Urinary Kallikrein group</arm_group_label>
    <other_name>Urinary Kallidinogenase</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Acute ischemic stroke or TIA within 72 hours;

          2. Intracranial ICA, MCA M1 segment stenosis (&gt;70%)

        Exclusion Criteria:

          1. &gt;70% Stenosis in an intracranial artery other than the culprit artery.

          2. &gt;50% Stenosis of an extracranial carotid or vertebral artery on the ipsilateral side.

          3. Perforator strokes based on MRI.

          4. Non-atherosclerotic lesion, for example, moyamoya disease, vascular inflammatory
             disease due to infection, autoimmunity diseases, developmental or genetic
             abnormalities, for example, fibromuscular dysplasia, sickle-cell anaemia, suspected
             vasospasm.

          5. Potential cardiac embolism as cause.

          6. Intracranial haemorrhage within 6 weeks.

          7. Concomitant intracranial tumour, aneurysm or arteriovenous malformation.

          8. Known contraindications for heparin, aspirin, clopidogrel or contrast.

          9. Haemoglobin &lt;10 g/dL, blood platelet count &lt;100 000, international normalisation ratio
             &gt;1.5, or other uncorrectable coagulopathies.Impaired liver function (alanine
             aminotransferase or glutamic oxalacetic transaminase ≥ 3×upper limit of normal) or
             renal function (serum creatinie ≥ 1.5mg/dl);

         10. A baseline modified Rankin Score of ≥3.

         11. Life expectancy of &lt;1 year due to the concomitant illness.

         12. Pregnant or lactating women.

         13. long-term statins users.

         14. History of mental instability or dementia.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Lou, Ph.D,M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>second affiliated hospital of Zhejiang University, school of medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The second affiliated hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>October 5, 2017</study_first_submitted>
  <study_first_submitted_qc>March 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 30, 2020</study_first_posted>
  <last_update_submitted>March 27, 2020</last_update_submitted>
  <last_update_submitted_qc>March 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intracranial Arteriosclerosis</mesh_term>
    <mesh_term>Brain Infarction</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Arteriosclerosis</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kallikreins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

